RAIR Health and UHCW Sign Data License Agreement

RAIR Health Limited, an applied AI and health data company focused on the development of proprietary insights from ophthalmic data and images, today announces it has signed a non-exclusive data license agreement with University Hospital Coventry and Warwickshire (“UHCW”) NHS Trust giving RAIR access to anonymised patient data in the field of ophthalmology.  

The anonymised patient data from UHCW will be used by RAIR to develop proprietary insights using advanced data sciences, including artificial intelligence and image-based machine learning. Such insights may help ophthalmologists to diagnose diseases earlier and to make better clinical decisions; to enable researchers to develop or refine treatments for patients; and to free up more staff time for direct patient care.  Ophthalmic data and images have also helped early detection of systemic and chronic disorders, which may provide exciting future opportunities to use AI and image-based machine learning for broader diagnostic purposes.

UHCW is responsible for managing two major hospitals in Coventry and Rugby, which between them serve a population of over a million people. The ophthalmology department is also one of the busiest in the UK with over 106,000 appointments in the last year. UHCW is also the principal teaching hospital for Warwick Medical School making it one of the UK's largest teaching trusts and an internationally recognised clinical research centre with a culture of innovation.  

In 2020, UHCW became home to one of the UK’s Digital Pathology Centres of Excellence, an initiative to build collaborative partnerships between the NHS, universities and industry, to develop technology solutions and products for more intelligent analysis of medical imaging and pathology data.

Professor Kiran Patel, Chief Medical Officer at UHCW NHS Trust, said: "UHCW continues to lead the field in data-led research and image analytics and we look forward to working with RAIR to extend this leadership into the field of ophthalmology and beyond. We hope to improve the care we provide to our patients by using RAIR’s model to provide improved access to data and we believe the application of artificial intelligence will help us achieve this.”

Roy Davis, Chairman of RAIR Health, said: "We are delighted to be working with one of the largest NHS teaching hospitals in the UK. The organisation’s excellence in imaging and significant data base provide a tremendous foundation for future data-led research and promises to accelerate medical advances, not just in ophthalmology, but across a number of systemic and chronic conditions which exhibit in the eye."

Under the terms of the agreement, UHCW will benefit from a right to royalties on any products or services which result from the insights derived from UHCW data and to participate in any future increase in the value of RAIR’s equity capital.